Q3 2025 · 13F-HR
ACORN CAPITAL ADVISORS, LLCholdings as filed
Filed 2025-11-17 · accession 0001636587-25-000060
$197.0M
Reported value
20
Positions
2025-09-30
Period end
The Brief · ACORN CAPITAL ADVISORS, LLC · Q3 2025
AI · grounded in 13F
ACORN CAPITAL ADVISORS, LLC established a new position in CG ONCOLOGY INC CGON valued at $45.6M. The fund also initiated new stakes in UROGEN PHARMA LTD URGN for $25.1M and PUMA BIOTECHNOLOGY INC PBYI for $21.9M. Additional new positions include TREVI THERAPEUTICS INC TRVI at $19.6M and TERNS PHARMACEUTICALS INC 430 at $14.8M. Total assets under management stand at $197M across 20 positions.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 156944100 | CGON | CG ONCOLOGY INC | $45.6M | 23.1% | 1,131,501 | Common | SOLE |
| M96088105 | URGN | UROGEN PHARMA LTD | $25.1M | 12.8% | 1,259,749 | Common | SOLE |
| 74587V107 | PBYI | PUMA BIOTECHNOLOGY INC | $21.9M | 11.1% | 4,131,299 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $19.6M | 9.96% | 2,144,844 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $14.8M | 7.52% | 1,971,264 | Common | SOLE |
| 137404109 | CADL | CANDEL THERAPEUTICS INC | $13.2M | 6.68% | 2,580,517 | Common | SOLE |
| 055477103 | BCAX | BICARA THERAPEUTICS | $10.2M | 5.16% | 643,382 | Common | SOLE |
| 68277Q105 | OKUR | ONKURE THERAPEUTICS INC | $7.8M | 3.96% | 2,839,674 | Common | SOLE |
| 74365U107 | TARA | PROTARA THERAPEUTICS INC | $7.6M | 3.87% | 1,752,115 | Common | SOLE |
| 92337C203 | VSTM | VERASTEM INC | $6.9M | 3.49% | 779,498 | Common | SOLE |
| 23256X407 | HELP | CYBIN INC | $4.3M | 2.19% | 734,394 | Common | SOLE |
| 14147L108 | CRDF | CARDIF ONCOLOGY INC | $4.0M | 2.05% | 1,962,084 | Common | SOLE |
| 05153U107 | AURA | AURA BIOSCIENCES INC | $3.7M | 1.87% | 595,744 | Common | SOLE |
| 09077B104 | BCABGBP | BIOATLA INC | $3.3M | 1.69% | 4,835,111 | Common | SOLE |
| 471871202 | JSPR | JASPER THERAPEUTICS | $3.3M | 1.67% | 1,382,640 | Common | SOLE |
| 00032Q104 | WHWK | WHITEHAWK THERAPEUTICS INC | $2.2M | 1.10% | 1,139,363 | Common | SOLE |
| 746964105 | QTTB | Q32 BIO INC. | $1.6M | 0.81% | 803,425 | Common | SOLE |
| 98420X103 | ASNSUSD | X4 PHARMACEUTICALS INC | $934,855 | 0.47% | 273,349 | Common | SOLE |
| 004890109 | ACRV | ACRIVON THERAPEUTICS INC | $733,479 | 0.37% | 405,237 | Common | SOLE |
| 92941V308 | VYNE | VYNE THERAPEUTICS INC | $199,434 | 0.10% | 586,572 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.